Bacterial Vaccine Discovery & Early Development ▲ Sign in to save

• ▲ JAN T. POOLMAN

  Johnson & Johnson (Netherlands) Immunology and Microbiology
  15.3k

  citations

  67

  h-index

  33

  Aachen papers
• ▲ Jeroen Geurtsen

  Sanofi (Netherlands) · Janssen (Netherlands) Biochemistry, Genetics and Molecular Biology
  3.61k

  citations

  25

  h-index

  42

  Aachen papers
• ▲ Chakkumkal Anish

  AstraZeneca (United States) · Janssen (Netherlands) Chemistry
  1.67k

  citations

  24

  h-index

  9

  Aachen papers
• ▲ Viktoria Dotz

  Janssen (Netherlands) Biochemistry, Genetics and Molecular Biology
  1.16k

  citations

  18

  h-index

  12

  Aachen papers
• ▲ Michel Beurret

  Janssen (Netherlands) Chemistry
  866

  citations

  14

  h-index

  8

  Aachen papers
• ▲ Eveline Weerdenburg

  Janssen (Netherlands) · Johnson & Johnson (Netherlands) Biochemistry, Genetics and Molecular Biology
  313

  citations

  3

  h-index

  8

  Aachen papers

6 results

• Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections

  2020 npj Vaccines article Immunology and Microbiology Immune responses and vaccinations Open access

  53

  citations
• Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry

  2022 Analytical Chemistry article Chemistry Mass Spectrometry Techniques and Applications Open access

  17

  citations
• Escherichia coli

  2023 Elsevier eBooks reference-entry Biochemistry, Genetics and Molecular Biology Escherichia coli research studies

  2

  citations
• Reply to Baird and Douglas

  2020 Clinical Infectious Diseases letter Medicine Infection Control in Healthcare Open access

  1

  citations

4 results